Dermatology Unit, "Sapienza" University of Rome, Viale del Policlinico 155, Rome, 00161, Italy.
Pathological Anatomy Unit, Ospedale San Filippo Neri, via G. Martinotti 20, Rome, 00183, Italy.
Immunotherapy. 2022 Mar;14(4):183-188. doi: 10.2217/imt-2021-0122. Epub 2021 Dec 22.
Dupilumab-related head and neck dermatitis is an increasingly reported clinical manifestation occurring in 4-10% of patients on dupilumab that was apparently not reported in clinical trials. Out of 62 adult patients treated with dupilumab for atopic dermatitis in the authors' center, four cases (6%) of head and neck dermatitis were observed, for which a skin biopsy was obtained. Onset occurred between 8 and 24 weeks after initiation of dupilumab, and the reaction resolved after 8-12 weeks. Histopathology and immunohistochemical findings support the authors' hypothesis that facial redness may be a toxic effect induced by dupilumab, although its pathogenesis still requires further investigation.
度普利尤单抗相关的头颈部皮炎是一种越来越多被报道的临床表现，在接受度普利尤单抗治疗的患者中发生率为 4-10%，而在临床试验中并未报告。在作者中心接受度普利尤单抗治疗特应性皮炎的 62 名成年患者中，观察到 4 例（6%）头颈部皮炎，为此进行了皮肤活检。发病发生在开始度普利尤单抗治疗后 8-24 周，反应在 8-12 周后消退。组织病理学和免疫组织化学发现支持作者的假设，即面部发红可能是度普利尤单抗引起的毒性作用，尽管其发病机制仍需要进一步研究。
